Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 3.65B +16.2% |
| Revenue (ttm) | n/a |
| Net Income | -428.73M |
| EPS | -4.67 |
| Shares Out | 98.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 450,696 |
| Open | 37.22 |
| Previous Close | 37.56 |
| Day's Range | 36.97 - 37.97 |
| 52-Week Range | 33.38 - 72.66 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 71.56 (+92.94%) |
| Earnings Date | Nov 9, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $71.56, which is an increase of 92.94% from the latest price.
News
Xenon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
Azetukalner advances toward epilepsy launch as MDD and pain catalysts approach.
Xenon Pharmaceuticals price target lowered to $80 from $82 at JPMorgan
JPMorgan analyst Tessa Romero lowered the firmâs price target on Xenon Pharmaceuticals (XENE) to $80 from $82 and keeps an Overweight rating on the shares. The firm updated the companyâsâŠ
Xenon Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026
The NDA is under review, with launch preparations targeting early 2028. X-NOVA2 MDD data are expected in December, while two pain candidates are planned for phase II in 2027; Q3 cash of $1.2 billion supports runway into 2029.
Xenon Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Azetukalnerâs NDA is filed, with a launch targeted for early 2028 and X-FIRST enrollment planned for H1 2027. MDD topline results are expected in December 2026, while pain programs target H1 2027 proof-of-concept studies.
Xenon Pharmaceuticals reports Q3 EPS ($1.11), consensus ($1.14)
âWeâve made significant progress advancing azetukalner with our recent NDA submission to the FDA for focal seizures and through ongoing scientific exchange opportunities. We continue to have great con...
Xenon Pharmaceuticals Earnings Call Transcript: Q3 2026
AZK's NDA was submitted, with launch preparations underway and $1.2B in cash and securities expected to fund operations into 2029. X-NOVA2 data are due in December, while pain candidates advance toward phase II.
Xenon Pharmaceuticals Earnings release: Q3 2026
Xenon Pharmaceuticals released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Xenon Pharmaceuticals Quarterly report: Q3 2026
Xenon Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 9, 2026.
Xenon Reports Q3 2026 Financial Results and Provides Business Update
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-...
Xenon Pharmaceuticals Slides: Investor presentation
Xenon Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon to Report Q3 2026 Financial Results on November 9, 2026
VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical develo...
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascu...
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (âXenonâ) common stock (NASDAQ: ...
Xenon Pharmaceuticals assumed with a Buy at Guggenheim
Guggenheim assumed coverage of Xenon Pharmaceuticals (XENE), which was previously covered by Yatin Suneja, with a Buy rating and $73 price target The firmâs ivnestment case rests on an epilepsyâŠ
Xenon Pharmaceuticals CFO buys 15,000 shares
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly purchased 15,000 shares at an average price of $37.32 for a value of $559,740, as reported in a regulatory filing.
Xenon Pharmaceuticals CEO buys 30,000 shares
Xenon Pharmaceuticals (XENE) CEO Ian Mortimer purchased 30,000 shares at an average price $37.38 for a value of $1,121,400, as reported in a regulatory filing.
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developi...
Xenon Pharmaceuticals Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Azetukalner's NDA for focal-onset seizures was filed after strong efficacy and safety results, with commercial launch preparations underway and four dose strengths planned. The phase III psychiatry program is paused for dose optimization, with key MDD data expected in Q1 2027. Early-stage pain programs are advancing to phase II.
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -...
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (âXenonâ) common stock (NASDAQ: XENE).
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel...
Xenon Pharmaceuticals falls -28.9%
Xenon Pharmaceuticals (XENE) is down -28.9%, or -$16.60 to $40.75.